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Summary 
BACKGROUND: There is relatively little information about endogenous biochemical 
changes in a response to plateletpheresis in healthy donors. We aimed to investigate the 
changes in different biochemical parameters including glycemic status, insulin resistance, 
iron status, lipid profile and inflammatory markers after plateletpheresis in healthy male 
donors with normal glycemic status. METHODS: In this study we enrolled 10 male 
subjects. The glycemic status in all subjects was assessed using an oral glucose tolerance 
test pre- and post-plateletpheresis at different time intervals (1, 8 and 22 days). Different 
biochemical parameters including glucose, HbA1c, insulin, lipids, uric acid, transferrin, 
ferritin, C-reactive protein and insulin resistance were measured. Repeated ANOVA was 
utilized for the purpose of statistical comparison of means between different days. 
RESULTS: Fasting glucose, transferrin, cholesterol, triglycerides, HDL-C, and LDL-C 
were significantly altered (-3.9%, p<0.05; -2.7%, p<0.05; -3.9%, p<0.05; 23.9%, p<0.05; 
-5.5%, p<0.01; and -9.2%, p<0.05 respectively) at day 1 following plateletpheresis. There 
was a gradual reduction in HbA1c and ferritin levels during the time-course of the study, 
and by day 22, both were significantly lower (-2.0%, p<0.01; -18.1%, p<0.05 
respectively) when compared to the pre-plateletpheresis levels. CONCLUSIONS: Post-
plateletpheresis, several biochemical parameters may change significantly in healthy 
donors. The changes were particularly evident one and 22 days after donation. The 
potential effects of plateletpheresis need to be considered when interpreting biochemical 
tests. 
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INTRODUCTION 
 Platelet transfusions are routinely needed as an essential part of treatment for patients 
undergoing cancer therapy, as well as for those with bleeding disorders, and for patients 
undergoing open-heart surgery, or organ transplantation[1]. Platelets can be harvested 
using plateletpheresis, a process whereby whole blood is removed from a donor, 
separating the blood into its components, keeping the platelets and returning the 
remaining blood components to the donor; or by separating platelets from units of whole 
blood [2, 3].  Platelets must be transfused within five days of collection due to their very 
short shelf-life [4]. Therfore there is a need for constant replenishment of the hospital 
supply. It is reported that platelet donations can be made up to 24 times per year [5]. 
However, there is relatively little information about the biochemical and physiological 
changes in response to plateletpheresis in healthy donors, especially because citrate is 
routinely used for the collection process to inhibit coagulation, and may lead to metabolic 
alkalosis. Indeed, it was reported that exposure to citrate during the apheresis procedure 
may acutely affect mineral and bone metabolism, leading to an increase in serum 
parathyroid hormone, and a fall in serum albumin, calcium and 25 hydroxy vitamin D 
levels. This has been shown to  compromise bone mineral density at the lumbar spine. 
[2]. Over the years, the thrombopoietic response to plateletpheresis has been investigated 
[3,4,5]. After plateletpheresis, platelet counts were reported to increase by some [3,4], 
and was reported to fall in one study [5].  In addition, serum ferritin levels of the female 
donors, but not male donors, has been reported to be decreased with increasing frequency 
of apheresis donation [5].  
A more recent study has investigated the effects of phlebotomy on insulin sensitivity and 
cardiovascular risk factors in patients with metabolic syndrome, and concluded that  
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consecutive reduction of body iron stores, lowered BP and resulted in improvements in 
markers of cardiovascular risk including  low-density lipoprotein/high-density lipoprotein 
ratio, and glycemic control. [6].  Whether such an effect is produced after plateletpheresis 
only is not known. Therefore, we aimed to investigate the effects of plateletpheresis on 
biochemical tests of glycemic status, insulin resistance, lipid profile, inflammatory 
markers and iron stores in plateletpheresis donors,   
MATERIALS AND METHODS  
Thirteen male first time donors were recruited from donation area at the apheresis 
facility. Exclusion criteria included:  diagnosed hypertension, treatment with oral 
hypoglycaemic drugs, insulin, or other drugs likely to modify insulin resistance and 
coagulation [7]. Subjects were also excluded if test results suggested abnormalities in 
glucose tolerance, or iron stores, or if they had a current acute symptoms, or if there were 
other contraindications to apheresis. After applying exclusion criteria three donors were 
rejected after the first visit due to impaired glucose tolerance. A standard donor 
questionnaire was used to verify eligibility for platelet donation, and a pre-procedure 
CBC is done to ensure that the donor platelet count is >150,000 per mm³, with donor 
consent being obtained before donation as usual. 
 
The study was approved by King Abdullah International Medical Research Center Ethics 
Committee, Jeddah, Saudi Arabia (Study number RCJ0611-183). Written informed 
consent was obtained from all participating subjects.  No participants with missing visits 
were included.  Each subject attended the apheresis area four times during the study 
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period, making the total number of visits by the ten subjects forty. Each subject was 
under venipuncture for eight times (pre and post 75 g oral glucose tolerance).  
  
On each visit subjects were weighed, their height measured, and body mass index 
calculated as weight (kg)/height (m2). There was no significant difference between BMI 
taken at the first visit (26.4 + 1.2 kg/m2) when compared to the last visit (26.4 + 1.1 
kg/m2), p = 0.91.   
  
At the baseline visit (visit A), venous blood samples were taken after overnight fasting 
(12 hours) immediately prior to platelet donation. Blood samples were collected into 
ethylenediaminetetra-acetic acid (EDTA), fluoride oxalate (grey top), and plain tubes. 
Oral glucose tolerance test (OGTT) was performed on each subject between 8 and 10 am, 
with further blood samples being collected 2 hours post glucose load into plain and grey 
top tubes. Within 10 minutes of collection, blood samples were centrifuged (3000 ×g) for 
10 minutes. Plasma glucose was measured immediately. Serum specimens for specialized 
tests, namely: insulin, lipid profile (total cholesterol, HDL-C, triglyceride), iron, ferritin 
and transferrin were stored at −80 °C until analysis. Once the results of the OGTT were 
available the glycaemic status of each participant was categorized according to WHO 
criteria [8]. All ten subjects were classified as having normal glucose tolerance following 
the first OGTT. Each subject also had their blood pressure measured using an automated 
equipment (V100 DINAMAP, General Electric) before blood collection.Plateletpheresis 
was undertaken later the same day using a standard protocol at the apheresis facility.  
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To monitor the effects of plateletpheresis on biochemical parameters, subjects returned 
for a second visit (visit B) 24 hours after plateletpheresis. A second OGTT was carried 
out as described at the first visit. Eight days later a third OGTT was performed (visit C), 
and 22 days after the first visit a fourth OGTT was performed (visit D). All participants 
were instructed to maintain their normal lifestyle and food intake before and between 
visits, to avoid potential affects on the results of biochemical tests independently of 
plateletpheresis. In addition, they were instructed not to take any medication or 
supplements during the period of the study.  The plateletphereses were performed over a 
period of 60 to 90 minutes, utilizing the Trima Accel, “Automated Blood Collection 
System”, (manufactured by TerumoBCT, Lakewood, Co, USA), at the blood bank 
(apheresis area), Department of Pathology and Laboratory Sciences, King Abdulaziz 
Medical City, Jeddah, which has been accredited by the American Association of Blood 
Bank (AABB) since 2007.  
Assays 
All biochemical tests were made using Architect autoanalyser (Abbott, USA) at the main 
laboratory of Jeddah, National Guard Hospital. The laboratory is accredited by the 
College of American Pathologists since 2002. The assays for glucose, CRP, cholesterol, 
HDL-cholesterol, triglycerides, uric acid, iron and transferrin were undertaken on an 
Architect c8000. LDL-cholesterol was calculated using the Friedewald formula [9]. 
Glycated hemoglobin (HbA1c) test was performed using a high-pressure liquid 
chromatography (HPLC) method on a G8-TOSOH Bioscience, Inc instrument. The 
principle of chemiluminescent immunoassay on Architect i1000 was utilized to measure 
insulin and ferritin levels in serum.   
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Indices of insulin resistance 
The index ISI-gly (insulin sensitivity index-glycaemia) was calculated based on the 
fasting and two hour glucose and insulin values using the following formula [10]:  
ISI-gly = 2/[(insulin x glucose) +1] 
Where insulin and glucoserepresent the sum of measurements of insulin (mU/L) and 
glucose mg/dL) taken at baseline and 2 hours during OGTT.  
 
Homeostasis model assessment-insulin resistance (HOMA-IR) and β-cell activity 
(HOMA-β) were calculated based on fasting levels only using the following two formula 
[11]: 
HOMA-IR = Fasting insulin (mU/L) x Fasting glucose (mmol/L) / 22.5 
β-cell function (%) = 20 x Fasting insulin(mU/L) / [Fasting glucose (mmol/L) - 3.5] 
 
Statistics 
The study was designed to detect mainly the difference between the baseline visit and 
other visits. Results are expressed as mean± SD or otherwise indicated. Data were 
transformed using natural logarithm (Ln) to approximate a normal distribution if 
necessary. Comparisons between means were performed using Paired Student’s t-test at 
95% confidence interval. Repeated measures one way ANOVA was used to compare 
means between different visits for the same individuals. Mauchly’s test statistic was 
evaluated for sphericity violation before concluding if there are significant differences 
between the variance of differences. P values <0.05 were considered significant. SPSS 
software (version 24) was used for statistical analysis.  
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RESULTS   
All 10 male subjects were from a Saudi population and had a normal glucose tolerance 
(NGT).  The age and body mass index (BMI) and other anthropometric measurements are 
shown in Table 1. Subjects were all under 50 years of age, and either of normal BMI, or 
overweight. 
 Changes in different biochemical parameters before and after blood donation are shown 
in Table 2. 
 
Glucose and insulin resistance 
Compared to the baseline levels, fasting plasma glucose (5.1 ± 0.6 mmol/L) was 
significantly lower (4.9 ± 0.5 mmol/L; p< 0.05) at visit B (Table 2).  Using one way 
repeated ANOVA, fasting glucose changes from A to D visits were not significant; F = 
1.03, p= 0.351.  Changes in post load (2 hours) plasma glucose levels were not 
significantly different from the baseline throughout the study.  Although fasting insulin 
increased by approximately 10.3% at visit B (10.7 ± 4.0 μIU/mL) compared to the 
baseline level (9.7 ± 4.5 μIU/mL), this failed to reach statistical significance. There was a 
negative, but statistically insignificant, effect on the index of insulin resistance (HOMA-
IR) at visit D, (-13.8%, p = 0.16) when compared to the baseline level. The insulin 
sensitivity index of ISI-gly increased following plateletpheresis by +5.8% at visit B but 
this increase was not significant (p = 0.43). At visit D, the ISI-gly returned almost to the 
baseline level.   
 
Glycated haemoglobin (HbA1c) 
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HbA1c fell in almost all subjects at visit D with a maximum reduction of -5.8%, 
increasing by +1.7 % in one subject only (Figure 1), and the mean level was significantly 
lower (5.37% ± 0.38, p<0.01) when compared to the baseline level (5.48% ± 0.32) 
(Figure 2, A). Moreover, the difference across the study period was highly significant; 
using repeated ANOVA; p= 0.008, F = 4.99 (Table 2).  
 
 
Lipid profile 
Table 2 Cholesterol fell at visit B by -3.9% (p<0.05), and continued throughout visit C (-
10.2%, p = 0.15) and visit D (-1.8%, p = 0.67).  However, repeated ANOVA was not 
significant (F = 1.35, p =0.281). Similar trend of reduced levels was noted in LDL-C test 
at visit B (-9.2%, p<0.05), C (-19.8%, p = 0.21) and D (-4.5%, p = 0.19), and similarly 
repeated ANOVA did not show a significant effect. Serum triglycerides showed a trend 
in the opposite direction, with levels increasing throughout the visits of B (23.9%, 
P<0.05), C (28.3% P = 0.34) and D (1.9%, p= 0.88), but with no significant differences 
using repeated ANOVA (F = 1.01, p = 0.36). The level of HDL-C decreased significantly 
at visit B,  (-5.5%, p<0.01) but not at visit C (-5.5%, p = 0.19) or D (2.4%, p = 0.33) 
when compared to the baseline level. However, using repeated ANOVA, the changes in 
HDL-C levels were not significant, F = 3.06, p = 0.075.   
   
Iron profile       
Iron levels fluctuated throughout the study, showing an increase at visits B (19.5%), and 
D (12.1%), but not C (-7.5%) when compared to the baseline level (visit A). Differences 
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throughout different visits were not significant using repeated ANOVA (F = 2.11, p = 
0.12).   
Serum transferrin was significantly lower at visit B (-2.7%, p<0.05) but not C (-4.6%, p= 
0.12) or D (2.3%, p=0.32).  
Following plateletpheresis iron stores which were assessed using serum ferritin, gradually 
decreased throughout different visits (B, -3.2%, p = 0.65; C, -9.6%, p = 0.44; D, -18.1%, 
p <0.05) (Figure 2, B). However, there were no significant changes using repeated 
ANOVA (F = 2.16, p = 0.12).  
 
Other indices 
After plateletpheresis, there was no change in levels of serum uric acid at any of the visits 
(Table 2). The inflammatory marker, CRP, increased at visit B (27.1%) and C (40.9%). 
At visit D the level became fell to near the baseline level (-9.1%). CRP was not 
significantly different using repeated ANOVA (F = 0.67, p = 0.44).  
 
DISCUSSION  
Previous studies on the changes in biochemical parameters after plateletpheresis in 
healthy individuals are limited; our findings show some potentially important effects. A 
reduction in iron stores after repeated plateletpheresis in males and females, and a 
correlation between iron depletion and frequency of pheresis donation in male donors has 
been noted previously  [12]. However, this was done by comparing stores in donors and 
non-donors, not by investigating the effect on the individual donors. In another study 
carried out on Japanese donors, serum ferritin levels were found to fall with donation-
frequency in female donors, [13]. In our study on first time male donors there was a 
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gradual decrease in iron stores, measured by ferritin level, following plateletpheresis over 
the study period, with statistical significance being noted at visit D. However, no values 
were found outside the reference range. This is the first report in literature of decreased 
iron stores following one single donation. Difference between our results and that of 
other studies could be due to difference in research design, as well as differences in 
studied population. 
The effect of plateletpheresis on glucose homeostasis and glycemic control is difficult to 
interpret. Levels of glucose (fasting and post glucose load) fluctuated throughout the 
study, with significantly (p <0.05) decreased fasting levels noted only at visit B, 
coinciding with non significant increases in  fasting insulin level (10.3%), β-cell activity 
(42.9%), and ISI-gly (5.8%). In addition, a significant effect was noted on A1c, with 
levels at visit D being significantly lower (p <0.01)  than at visit A, coinciding with a non 
significant decrease in the index of insulin resistance (HOMA- IR) of 13.8.  
 
The non-significant changes in insulin resistance across different visits could be due to 
the limitation of the simple methods (i.e HOMA-IR and ISI-gly) utilized in this study 
and/or the small sample size. The use of reference methods such as euglycemic clamp or 
frequently sampled intravenous glucose tolerance (FSIVGT) might be more sensitive to 
detect such changes.   
 
The overall decrease in the mean of HbA1c percentage over the study period suggests an 
improvement in one of the main diagnostic test of diabetes. A decrease in HbA1c with a 
maximal reduction at the fourth week following whole blood donation was obtained by 
Starkman  et al., [14]. However, this is the first time to show that, not only whole blood 
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donation but even plateletpheresis can reduce HbA1c towards a lower level.  Such an 
effect was expected after whole blood donation but not after plateletpheresis because the 
amount of whole blood lost in this process is limited (80 to 100 mL) compared to whole 
blood donation (450 mL). The possible reason behind this decrease is unclear but it could 
be due to other artefactual effects. For example, the status of RBCs viability, integrity 
and lysis might be affected by the process of cell separation and citrate addition (as 
inhibitor) before the RBCs are returned to the donor. If the old RBCs are affected by such 
factors then the new released RBCs to the circulation will be for the purpose of selective 
removal of the old ones. Unfortunately no previous study has discussed such effects as 
this may need further investigations. Another possible reason is the mobilization effect of 
plateletpheresis [15, 16] on different blood components including RBCs not only the 
platelet. 
To interpret  the value of the change in A1c, the effect of reference change values (RCV) 
must be discussed. RCV is defined as the critically significant changes between two 
results. It is important for determining whether apparent changes in serial results reflect 
real changes or can be accounted for by biological variation alone [17]. RCV of ±5.4% 
was previously reported for HbA1c in healthy individuals using the same HPLC method 
but without any intervention [18]. However, the RCV in our population was not 
determined, and despite the statistically significant decrease in HbA1c at visit D in our 
participants, the total change in percentage compared to baseline was only approximately 
-2.0%, hence does not exceed the previously reported RCV of ±5.4%.  
Changes in HbA1c in each involved participant did not exceed the limit of RCV of 
±5.4% except in one subject where the change was -5.8%. Variations in HbA1c between 
different individuals after whole blood donation was investigated before and it was 
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concluded that it may depend on the effectiveness of erythropoiesis which subsequently 
depends on sufficient iron stores [19]. Therefore, the same conclusion may be applied on 
HbA1c variability between different subjects after plateletpheresis.   Whether our 
findings of a decrease in HbA1c reflects a real effect of plateletpheresis in reducing 
HbA1c levels in non-diabetic individuals is worthy of further investigation, especially in 
type 2 diabetic donors. Our findings may also suggest that lower ferritin levels at visit D 
compared to baseline could contribute to enhanced insulin sensitivity for HOMA-IR. This 
observation is in line with the previously published results about whole blood donation 
[20]. Hence, it could be suggested that platletpheresis may increase the removal of free 
transition metals, including iron from the body. This may lead to a reduction in the 
oxidation susceptibility of end products of serum glycated proteins, which are thought to 
have potential toxic effects resulting in increased insulin resistance [21, 22]. However, if 
plateletpheresis is associated with the selective removal of old RBCs, due to the reasons 
suggested above, then this may lead to the mobilization of iron stores to make new RBCs.  
 
At the first visit 24 hours after plateletpheresis (visit B), total cholesterol, and its 
estimated fractions were significantly decreased, in contrast to triglycerides which was 
significantly increased. Such changes may be important to consider if the patient is being 
treated with lipid lowering agents. In addition, the medical assessment of new donors 
recruited to platletpheresis program should include a venous blood sample taken prior to 
initial donation. This trend of decrease in blood cholesterol and LDL-C after 
plateletpheresis is consistent with the control subjects involved in Houschyar et.al, study 
[6]. As triglycerides level is diet dependent then the increased level can be related to the 
timing of the last meal of each individual subject.  
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When the RCV principle is applied to lipid parameters using the same methods and auto-
analyser (Architect c8000), the RCVs for glucose, total cholesterol, triglyceride and 
HDL-C and were reported as ±14.63%, ±14.19%, ±46.62% and ±20.51% respectively 
[23]. Based on these values, changes in the analytes were not considered clinically 
significant.  
   
After plateletpheresis, no significant changes were observed for serum urate. 
Furthermore, although a progressive increase in serum CRP was noticed after 
plateletpheresis for up to 8 days, the difference was not significant from the baseline 
level. This increased level of CRP could be due to the induced citrate solution during the 
process of platletpheresis, but this point may need further investigation.  
 
One of the main limitations of the present study is the relatively small number of 
involved subjects. However, the numbers were sufficient to detect changes in this pilot 
study, and to stimulate further studies. The second limitation was the use of simple 
surrogate indices of insulin resistance only, which are appropriate for preliminary 
investigations but they do suffer from some important limitations that have been 
discussed previously [24, 25].  
 
In summary, although changes in glycaemic control, serum lipids and iron stores are not 
likely to be clinically significant, they do suggest that there needs to be a careful 
interpretation of the blood test results of individuals after plateletpheresis. Such potential 
changes can be detected at 1 and 22 days after donation. Future larger studies with  more 
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than one episode of platelet donation may show a significant clinical change for the same 
parameters  
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Figure 1. HbA1c changes from the baseline (visit A) until day 22 post plateletpheresis 
(visit D). Horizontal line represents each of 10 individual subjects. Vertical line is the 
HbA1c level (%). Each bar represents 95% confidence interval (CI). Circle in the middle 
of the bar is the mean of HbA1c obtained from the four visits (A, B, C and D). The 
number on top of each bar represents the difference in percentage between HbA1c level 
at visit A when compared to visit D for this particular subject.  
 
Figure 2. Changes in the mean of both tests, HbA1c (Fig. A) and ferritin (Fig. B) before 
(visit A) and after (visits B, C and D) plateletpheresis. *p<0.05, **p<0.01 when 
compared to the baseline level (visit A). Bars represent 95%CI.  
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